Confirming Diabetes Diagnosis through Repeat Fasting Plasma Glucose Testing
Rationale for Confirmatory Testing
- The American Diabetes Association recommends confirming the diagnosis of diabetes through repeat fasting plasma glucose testing when a single test exceeds the diagnostic threshold without symptoms or crisis, to ensure accurate diagnosis and appropriate treatment 1, 2
- Diagnosis of diabetes requires two abnormal test results, either from the same sample using different tests or the same test repeated on a separate occasion, in the absence of unequivocal hyperglycemia 1, 2
Practical Considerations for Repeat Testing
- The American Diabetes Association suggests ensuring proper fasting of at least 8 hours with no caloric intake before performing the confirmatory fasting plasma glucose test 1
- Samples should be processed promptly, with glucose samples centrifuged and separated immediately to avoid preanalytic variability that can falsely lower results if left at room temperature 2
Interpretation of Confirmatory Results
- If repeat fasting plasma glucose is ≥126 mg/dL, diabetes is confirmed, and comprehensive diabetes management should be initiated, including lifestyle modifications and consideration of metformin, as recommended by the American Diabetes Association 1
- If repeat fasting plasma glucose is 100-125 mg/dL, the patient has impaired fasting glucose, warranting intensive lifestyle intervention and consideration of repeat testing in 3-6 months, according to the American Diabetes Association guidelines 1
Important Caveats
- The American Heart Association and American Diabetes Association acknowledge that preanalytic variability is particularly problematic with glucose measurements, and samples left at room temperature without prompt centrifugation can show falsely low values due to ongoing glycolysis 2
- The American Diabetes Association recommends continuing to optimize blood pressure control and cardiovascular risk reduction in patients with hypertension, regardless of glucose status, to reduce cardiovascular risk 5